Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | MLNR | O43193 | 3/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401960 | 0.85 | ALDH1A1 (0.47) | KMT2AALDH1A1MEN1POLBSMN1; SMN2 | |
| SCHEMBL4401054 | 0.85 | HTT (0.40) | KMT2AALDH1A1POLBCHRM3HTT | |
| SCHEMBL4400538 | 0.82 | SMN1; SMN2 (0.43) | KMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL4394376 | 0.80 | CCR5 (0.51) | KMT2AALDH1A1MEN1POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4399450 | 0.80 | CASR (0.44) | KMT2AMEN1 | |
| SCHEMBL4393209 | 0.79 | SMN1; SMN2 (0.46) | KMT2AALDH1A1MEN1SMN1; SMN2MLNR | |
| SCHEMBL13672947 | 0.79 | ALDH1A1 (0.34) | KMT2AALDH1A1MEN1POLBCHRM3 | |
| SCHEMBL14472756 | 0.78 | MLNR (0.35) | KMT2AALDH1A1MEN1SMN1; SMN2MLNR | |
| SCHEMBL4393787 | 0.78 | CASR (0.42) | KMT2AMEN1CXCR4 | |
| SCHEMBL4391651 | 0.77 | EPHX2 (0.38) | KMT2AALDH1A1MEN1SMN1; SMN2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605261-B2 | Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AMGEN INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20070173502-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | US | disclosed |
| US-20040053925-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | PROSKELIA SAS (FR) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053925-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | HRH4, HRH2, RPS2 | KMT2A 3889/4885ALDH1A1 3828/4885MEN1 3080/4885 |
| US-20070173502-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | RPS2, NOX5, PRMT5 | KMT2A 4161/4885ALDH1A1 3190/4885MEN1 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.